23.85
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
What analysts say about NewAmsterdam Pharma Company N.V. Equity Warrant stockHigh-impact investment strategies - Autocar Professional
Arizona State Retirement System Buys New Shares in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Defense World
What analysts say about NewAmsterdam Pharma Company N.V. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives NewAmsterdam Pharma Company N.V. stock priceRapid wealth creation - Autocar Professional
What makes NewAmsterdam Pharma Company N.V. stock price move sharplyDaily Breakout Picks - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant Stock Analysis and ForecastHigh-impact stock picks - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025 - GlobeNewswire
Major Alzheimer's Discovery: Cardiovascular Drug Shows Promising Brain Health Benefits in 1,727 Patients - Stock Titan
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceHigh-yield capital appreciation - jammulinksnews.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatilityFree High-Profit Stock Picks - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant a good long term investmentExceptional return forecasts - Autocar Professional
Is NewAmsterdam Pharma Company N.V. a good long term investmentExplosive portfolio gains - jammulinksnews.com
why newamsterdam pharma company n.v. equity warrant stock attracts strong analyst attentionFree Risk Assessment Services - Newser
When is the best time to buy NewAmsterdam Pharma Company N.V. stockFree Access to Investment Community - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs Group - Defense World
How NewAmsterdam Pharma Company N.V. stock reacts to Fed policy changesFree Capital Allocation Plans - Newser
Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com Australia
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $42.89 Consensus Price Target from Analysts - Defense World
Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionWatchlist Winner Update - Newser
Why NewAmsterdam Pharma Company N.V. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How NewAmsterdam Pharma Company N.V. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyAlpha Stock Ideas - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):